We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

20 hedge funds and large institutions have $4.36M invested in Aprea Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

19% more capital invested

Capital invested by funds: $3.66M → $4.36M (+$695K)

1.32% more ownership

Funds ownership: 23.46% → 24.78% (+1.3%)

5% less funds holding

Funds holding: 21 → 20 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
20
Holders Change
-1
Holders Change %
-4.76%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
3
Closed
2
Calls
$621K
Puts
–
Net Calls
+$621K
Net Calls Change
+$67K

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$179K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$30.1K
3
Morgan Stanley
Morgan Stanley
New York
+$10.9K
4
Wells Fargo
Wells Fargo
California
+$8
5
Bank of America
Bank of America
North Carolina
+$4

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$9.64K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.91K
3
BlackRock
BlackRock
New York
-$2.97K
4
BOC
Bull Oak Capital
California
-$162
5
Creative Planning
Creative Planning
Kansas
-$105

APRE Hedge Fund Activity: Q4 2023 in Review

20 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2023, worth a combined $4.36M — up 19% from $3.66M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of APRE and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.

The largest buyer was Royal Bank of Canada, adding an estimated $179K. The largest seller was Walleye Capital, cutting an estimated $9.64K.

  • 20 institutional investors held Aprea Therapeutics (APRE) as of Q4 2023, down from 21 in Q3 2023.
  • Funds reported $4.36M of Aprea Therapeutics stock for Q4 2023, up 19% quarter-over-quarter.
  • 1 fund opened new Aprea Therapeutics positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest Aprea Therapeutics buyer in Q4 2023 was Royal Bank of Canada, an estimated $179K added.
  • The largest Aprea Therapeutics seller in Q4 2023 was Walleye Capital, an estimated $9.64K sold.

Based on aggregated 13F filings for Q4 2023.